Prescient Healthcare Group has annoucned the completion of the integration of healthcare consultancies Uptake and Dolon under a single global Prescient brand.
The action brings together more than 550 pharmaceutical and biotech specialists across seven international offices.
The move follows on from Prescient’s purchase of commercial healthcare consultancy Uptake in January of this year and London-based value, pricing and market access consultancy Dolon in March.
Prescient said that the addition of Uptake had strengthened capabilities in commercial strategy and planning, early commercialisation and launch, while Dolon added specialist expertise in pricing and market access, particularly across complex therapeutic areas such as oncology and rare diseases.
One platform across the drug lifecycle
The completed integration is intended to give pharma and biotech companies a single point of access to capabilities spanning early clinical development, commercialisation, product launch and lifecycle management.
Prescient said in its statement that the unified organisation will bring together four core areas: commercial strategy and planning; competitive strategy; medical affairs and real-world evidence (RWE) and value, pricing and access.
This reflects a wider shift towards more integrated decision-making in biopharma, where clinical evidence, competitive intelligence, commercial positioning and reimbursement considerations increasingly need to be considered together rather than as separate stages of drug development.
Prescient already positions its medical and evidence capabilities around early integration with R&D and commercial teams, while its market access offering includes RWE study design, epidemiology, payer insights and pricing and reimbursement strategy.
Jason McKenna, CEO of Prescient, said the integration reflected how the organisation was already working, with teams from the three businesses collaborating on increasingly complex client challenges.
Bringing everything together under the Prescient name reflects how the platform works today, as one integrated organisation combining specialist expertise across commercial, medical and market access disciplines.
Debbie Allman, Prescient’s Chief Growth Officer and Global Practice Lead, Commercial, added that clients “don't experience challenges in functional silos”, with scientific, commercial, competitive and access decisions increasingly influencing one another.
Our role is to connect those perspectives in practical ways that help clients make stronger decisions and execute with confidence.
Consultancy consolidation
The move also marks the final stage of the businesses’ operational integration.
Dolon’s website and content transitioned to Prescient on 13 August, with its specialist team and expertise now incorporated into the broader Prescient platform.
For biopharma companies, the consolidation should simplify access to multidisciplinary consulting expertise as drug development and commercialisation become increasingly data-driven and interconnected.
Prescient said that the combined structure is designed to help clients make decisions earlier across the product lifecycle and connect scientific, commercial and market access perspectives.
